[{"abstract": "The blockbuster pharmaceutical merger has put new pressure on Congress and the White House to overhaul the corporate tax code.", "web_url": "https://www.nytimes.com/2015/11/24/business/drug-merger-reignites-tax-reform-discussion.html", "snippet": "The blockbuster pharmaceutical merger has put new pressure on Congress and the White House to overhaul the corporate tax code.", "lead_paragraph": "WASHINGTON \u2014 For almost four years, Congress and the White House have done little to make their long-promised overhaul of the corporate tax code a reality. Now the blockbuster pharmaceutical merger of Pfizer and Allergan has put new pressure on all sides to act.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24corptax-web1/24corptax-web1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24corptax-web1/24corptax-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24corptax-web1/24corptax-web1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24corptax-web1/24corptax-web1-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24corptax-web1/24corptax-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer-Allergan Merger Reignites Tax Reform Discussion", "kicker": null, "content_kicker": null, "print_headline": "Drug Merger Reignites Tax Reform Discussion", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Calmes, Jackie", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 4, "major": "N"}, {"name": "subject", "value": "Tax Shelters", "rank": 5, "major": "N"}, {"name": "subject", "value": "United States Politics and Government", "rank": 6, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 7, "major": "N"}, {"name": "subject", "value": "Relocation of Business", "rank": 8, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 9, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 10, "major": "N"}], "pub_date": "2015-11-24T02:20:32+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Jackie Calmes", "person": [{"firstname": "Jackie", "middlename": null, "lastname": "Calmes", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/92d72a39-66e0-5992-b462-0b735f834bd4", "word_count": 1051, "uri": "nyt://article/92d72a39-66e0-5992-b462-0b735f834bd4"}, {"abstract": "The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action.", "web_url": "https://www.nytimes.com/2015/11/25/business/dealbook/why-pfizers-deal-may-change-the-system-oftaxing-multinationals.html", "snippet": "The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action.", "lead_paragraph": "Pfizer\u2019s proposed merger with Allergan is a blockbuster deal in the pharmaceutical industry. History may remember the deal instead for finally killing off the United States\u2019 outdated approach to taxing multinational corporations.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-articleLarge.jpg", "height": 395, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 395}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-jumbo.jpg", "height": 674, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-superJumbo.jpg", "height": 1348, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/db-deduction-web1/db-deduction-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Why Pfizer\u2019s Deal May Change the System of\u00a0Taxing Multinationals", "kicker": "Standard Deduction", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "subject", "value": "Law and Legislation", "rank": 5, "major": "N"}], "pub_date": "2015-11-24T15:10:41+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Victor Fleischer", "person": [{"firstname": "Victor", "middlename": null, "lastname": "Fleischer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/df2d37a0-8ad2-5245-aed0-c690132aa819", "word_count": 917, "uri": "nyt://article/df2d37a0-8ad2-5245-aed0-c690132aa819"}, {"abstract": "The deal with Allergan will cut taxes and add solid assets, but it is also prompting Pfizer to defer a decision on splitting up until 2018.", "web_url": "https://www.nytimes.com/2015/11/25/business/dealbook/pfizers-desire-to-split-has-faded.html", "snippet": "The deal with Allergan will cut taxes and add solid assets, but it is also prompting Pfizer to defer a decision on splitting up until 2018.", "lead_paragraph": "Pfizer\u2019s huge deal for Allergan will lower the drugmaker\u2019s taxes, add solid assets such as Botox and reduce leverage. But it has also created a material adverse event. Pfizer is delaying a decision on whether to split the company by two years.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-superJumbo.jpg", "height": 1366, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp1/24DB-PFIZERjp1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer\u2019s Desire to Split Has Faded", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 5, "major": "N"}], "pub_date": "2015-11-24T17:05:17+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/bd5db93b-0027-56de-ac34-f020cfc98ed5", "word_count": 353, "uri": "nyt://article/bd5db93b-0027-56de-ac34-f020cfc98ed5"}, {"abstract": "The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses.", "web_url": "https://www.nytimes.com/2015/11/25/business/dealbook/pfizer-and-allergan-deal-comes-with-an-extensive-prenup.html", "snippet": "The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses.", "lead_paragraph": "Pfizer and Allergan thought up several situations where their blockbuster $152 billion merger agreement could meet resistance, including from shareholders, regulators and lawmakers, and even rival suitors.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg", "height": 395, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 395}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-jumbo.jpg", "height": 674, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-superJumbo.jpg", "height": 1349, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer and Allergan Deal Comes With an Extensive Prenup", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "House of Representatives", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Encounter (Magazine)", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Senate", "rank": 7, "major": "N"}, {"name": "persons", "value": "Franken, Al", "rank": 8, "major": "N"}], "pub_date": "2015-11-24T22:36:21+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Liz Moyer", "person": [{"firstname": "Liz", "middlename": null, "lastname": "Moyer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691", "word_count": 577, "uri": "nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691"}]